$32.37 +0.07 (0.22%) Myriad Genetics Inc - NASDAQ

Jul. 26, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 32.37
Trade Time: Jul 26 04:00 PM Eastern Daylight Time
Change: +0.07 (0.22%)
Prev Close: 32.30
Open: 32.16
Bid: 32.37
Ask: 32.38
  1. No results found.
  1. RS Investment Sells Stake in Debt Collection Company

    GuruFocus | Feb. 17, 2016 | 14:14PM EST
  2. Chuck Royce Reduces Several Positions in 4th Quarter

    GuruFocus | Feb. 5, 2016 | 17:30PM EST
  3. Apple Rises On Upgrade, China; Lululemon Jumps On Brighter View

    IBD | Jan. 12, 2016 | 13:51PM EST
  4. 4 Stocks Moving On Breast-Cancer News

    IBD | Dec. 10, 2015 | 16:04PM EST
  5. Benzinga's Top Upgrades

    Benzinga | Dec. 8, 2015 | 09:01AM EST
  6. Myriad RBM DiscoveryMAP Technology Identifies Novel Biomarkers That May Predict Increased Risk of Cardiovascular Events in Patients With Diabetes

    Benzinga | Nov. 16, 2015 | 07:12AM EST
  7. Crescendo Bioscience Vectra DA Data to be Presented at American College of Rheumatology 2015 Annual Meeting

    Benzinga | Nov. 7, 2015 | 20:05PM EST
  8. Top 4 NASDAQ Stocks In The Research Services Industry With The Highest EPS

    Benzinga | Oct. 19, 2015 | 04:18AM EST
  9. US Stock Futures Signal Higher Start On Wall Street

    Benzinga | Oct. 7, 2015 | 08:05AM EST
  10. Myriad Genetics, Tufts Health Plan Sign 3-Year Contract to Cover Prolaris for Members With Localized Prostate Cancer

    Benzinga | Oct. 7, 2015 | 07:07AM EST
  11. Myriad Genetics and Tufts Health Plan Sign Agreement to Cover Prolaris(R) for Members With Localized Prostate Cancer

    Benzinga | Oct. 7, 2015 | 07:05AM EST
  12. Genomics Out Of 'Caveman Era,' But Still A Ways To Go

    IBD | Oct. 5, 2015 | 08:02AM EST
  13. Myriad Genetics Presents New Data on Its Companion Diagnostic and Prostate Cancer Tests at the European Society for Medical Oncology Annual Meeting

    Benzinga | Sep. 24, 2015 | 07:05AM EST
  14. Top 4 NASDAQ Stocks In The Research Services Industry With The Highest Revenue

    Benzinga | Sep. 17, 2015 | 04:23AM EST
  15. Myriad Announces Favorable Medicare Final Coverage Decision for the ProlarisR) Test

    Benzinga | Aug. 13, 2015 | 07:06AM EST
Trading Center